Park Ave Peptides — Clinical Reference Library — For Professional Use Only

Regenerative & Musculoskeletal Research
Reference Compound
TB-500 is a synthetic version of the active region of Thymosin β4, a naturally occurring 43-amino-acid actin-sequestering peptide. The principal mechanism in the literature is binding to G-actin via the conserved actin-binding motif (KLKKTET), regulating cytoskeletal dynamics and enabling cell migration during tissue repair.
At a Glance
Quality Documentation
Lot PAP-TB500T-240118-A01 — Reference
Field of Medicine — Regenerative & Musculoskeletal Research
Regenerative Medicine and Cardiovascular Research.
TB-500 is a synthetic fragment corresponding to the active region of Thymosin Beta-4 (Tβ4), a 43–amino-acid actin-sequestering peptide naturally abundant in platelets and wound fluid.
Tβ4 binds G-actin to regulate cytoskeletal dynamics, supports cell migration, and upregulates expression of laminin-5, integrins, and angiogenic factors. It has been investigated for roles in cardiac repair, corneal wound healing, and dermal regeneration.
Reference Compound
TB-500 (Thymosin Beta-4)
02 — Science
03 — Pathway
Pathway Summary
TB-500 is a synthetic version of the active region of Thymosin β4, a naturally occurring 43-amino-acid actin-sequestering peptide. The principal mechanism in the literature is binding to G-actin via the conserved actin-binding motif (KLKKTET), regulating cytoskeletal dynamics and enabling cell migration during tissue repair.
TB-500 is a synthetic version of the active region of Thymosin β4, a naturally occurring 43-amino-acid actin-sequestering peptide. The principal mechanism in the literature is binding to G-actin via the conserved actin-binding motif (KLKKTET), regulating cytoskeletal dynamics and enabling cell migration during tissue repair.
Secondary mechanisms include upregulation of laminin-5 and integrin expression supporting endothelial cell migration, suppression of inflammatory cytokines in injury models, and angiogenic effects mediated through pathways overlapping with VEGF signaling.
Like BPC-157, the evidence base is preclinical. Human work to date is limited to early-phase trials in dry-eye and dermal indications conducted with the parent Thymosin β4 sequence rather than TB-500 specifically.
04 — Lab Reference
For licensed research and clinical evaluation only. Not dosing guidance.
Reconstitution
Bacteriostatic water (0.9% benzyl alcohol) or sterile water. Add diluent slowly along the vial wall — do not inject directly onto the lyophilized cake. Swirl gently until fully dissolved.
Storage
Lyophilized: −20°C long term; 2–8°C short term (weeks). Protect from light.Reconstituted: 2–8°C, generally up to 14–28 days depending on compound.
Quality
≥99% purity by HPLC. Identity confirmed by mass spectrometry. Independent third-party verification on every lot. COA available per lot.
Handling notes —Avoid repeated freeze–thaw cycles. Do not shake vigorously after reconstitution.
Need a full protocol brief?
Reconstitution worksheets, concentration reference cards, and sample COA for verified accounts.
05 — Comparative
See molecular profile, pharmacokinetics, and handling next to related compounds in the same family.
06 — Citations
The following sources are representative of the literature describing TB-500 (Thymosin Beta-4). A full annotated citation list with PubMed identifiers is available on request.
See also the glossary of research terms and the full peptide library.
cGMP facility · Third-party tested · Cold-chain shipping · 24-hour COA on request